CRA was retained on behalf of a pharmaceutical manufacturer to assess the commercial success of drugs indicated for the treatment of severe acne and the nexus between that success and the patents at issue. At issue was the combination use of active ingredients. CRA found commercial success and a nexus between that success and the patents at issue. Although the manufacturer provided patient coupons for copay relief, CRA found that pricing and marketing activity were not undue contributors to commercial success.
CRA consultants recognized among leading IP professionals in the 2025 IAM Strategy 300
Daniel McGavock, Robert Goldman, and Dr. Richard Razgaitis were recognized as leading IP strategists by Intellectual Asset Management (IAM) in the latest...